Citi Upgrades BioAge Labs Stock on Promising Obesity Drug Potential
Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.
/ 84 items
#NVO↓
Novo Nordisk Chairman and Six Directors Resign Amid Foundation Power Struggle
Novo Nordisk's chairman Helge Lund and six independent directors are stepping down after failing to reach agreement with majority shareholder over pace of board transformation as company faces market challenges.
WeightWatchers Partners with Amazon for GLP-1 Delivery
WeightWatchers partners with Amazon Pharmacy to offer easier access to GLP-1 weight-loss drugs like Wegovy and Zepbound, especially for customers in rural areas with faster delivery options.
Trump Vows Sharp Cut to Ozempic Price, Sending Novo Nordisk Shares Tumbling
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.
FDA Facility Issue May Delay Regeneron's EYLEA HD Launch
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.